Study protocol and preliminary results from a mono-centric cohort within a trial testing stereotactic body radiotherapy and abiraterone (ARTO-NCT03449719).

Giulio FrancoliniBeatrice DettiVanessa Di CataldoPietro GarlattiMichele AquilanoAndrea AllegraSara LucidiCecilia CerbaiLucia Pia CicconeViola SalvestriniGiulia StocchiBarbara GuerrieriLuca VisaniMauro LoiIsacco DesideriMonica MangoniIcro MeattiniLorenzo Livi

Published in: La Radiologia medica (2022)

SBRT + Abiraterone treatment was safe and well tolerated, non-significant trend in terms of PSA drop and biochemical response at 3 months was detected in SBRT arm. Interestingly, CTCs detection in this selected cohort of oligo-mCRPC was lower if compared to historical data of unselected mCRPC patients.

Keyphrases

study protocol
radiation therapy
end stage renal disease
prostate cancer
randomized controlled trial
clinical trial
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
squamous cell carcinoma
circulating tumor cells
big data
open label
replacement therapy
real time pcr
double blind